Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00NXT
|
||||
| Former ID |
DNCL003798
|
||||
| Drug Name |
Xmab 5871
|
||||
| Synonyms |
XmAb 5871 (TN)
|
||||
| Indication | Autoimmune diabetes [ICD10:E08-E13] | Phase 2 | [549317] | ||
| Company |
Amgen; Xencor
|
||||
| Target and Pathway | |||||
| Target(s) | CD32b | Target Info | Modulator | [531971] | |
| B-lymphocyte antigen CD19 | Target Info | Modulator | |||
| NetPath Pathway | Leptin Signaling PathwayNetPath_19:IL-7 Signaling Pathway | ||||
| PANTHER Pathway | B cell activation | ||||
| Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | ||||
| BCR signaling pathwaybcr_5pathway:BCR signaling pathway | |||||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cellR-HSA-1257604:PIP3 activates AKT signaling | ||||
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||||
| Constitutive Signaling by Aberrant PI3K in Cancer | |||||
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.